Recall Register

Food, drugs, devices › Breckenridge Pharmaceutical, Inc

Drug recall: Duloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, Manufactured by Towa Pharmaceutical Europe,

FDA enforcement event 96707 · Class II · initiated 14 Apr 2025 · status Ongoing

DrugVoluntary: Firm initiated2 product recordsBerlin, CT

Breckenridge Pharmaceutical, Inc (Berlin, CT) initiated this drug recall on 14 Apr 2025; FDA lists 2 product records under event 96707, classified Class II.

FDA defines Class II as a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. 79% of the 322 drug enforcement events initiated in 2025 carry the same class.

Status: Ongoing. Initiation: voluntary: firm initiated. Breckenridge Pharmaceutical, Inc has 21 enforcement events on this register, with a median of 1 product record per event.

Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.

Recalling firm

Breckenridge Pharmaceutical, Inc, Berlin, CT.

Reason for recall

"CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit."

Distribution

"US Nationwide."

Product records

Recall numberProductQuantityClassStatusReport date
D-0387-2025Duloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L., Distributed by Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922, NDC# 51991-748-1016,473 bottlesClass IIOngoing30 Apr 2025
D-0388-2025Duloxetine Delayed-Release Capsules USP, 30 mg, a.) 90-count bottles (NDC# 51991-747-90), b.) 1000-count bottles (NDC 51991-747-10), Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L. Distributed by Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922343,344 bottlesClass IIOngoing30 Apr 2025

Context

79%of 2025 drug events are Class II322 events that year
2product records in this eventfirm median: 1
21events on this register for the firm

Other enforcement events for Breckenridge Pharmaceutical, Inc

InitiatedProduct (first record)TypeClassRecords
4 Jun 2026Duloxetine Delayed-Release Capsules, USP, 30mg, 1000 Capsule bottles, Rx only, Manufactured. by: Towa Pharmaceutical EurDrugClass II2
21 Apr 2026Duloxetine Delayed-Release Capsules USP, 60mg, Rx Only, 90-count bottle, Mfr. by Towa Pharmaceutical Eurpoe S.L., MartorDrugClass II1
24 Nov 2025Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals EuDrugClass II2
9 Oct 2025Duloxetine Delayed-Release Capsules, USP, 60 mg, a.) 90-count bottle (NDC: 51991-748-90), b.)1000-count bottle (NDC 5199DrugClass II1
8 Aug 2025Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa PharmaceuticaDrugClass II1
25 Jul 2025Duloxetine Delayed-Release Capsules, USP, 60 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa PharmaceuticaDrugClass II1
15 Jul 2025Duloxetine Delayed-Release Capsules, USP, 60mg, 1,000-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. DrugClass II1
30 Jun 2025Duloxetine Delayed-Release Capsules, USP, 40mg, 30-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. MarDrugClass II1
26 Mar 2025Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx Only, 1,000 Capsules per bottle, Manufactured by: Towa PharmaceuticaDrugClass II1
28 Feb 2025Duloxetine Delayed-Release Capsules, USP, 60mg, Rx Only, 1000-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. MDrugClass II3

All 21 events for Breckenridge Pharmaceutical, Inc

Questions and answers

Why was this drug recalled?

FDA's record gives the reason for recall as: "CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit."

What does Class II mean?

FDA classifies recalls by relative degree of health hazard. Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Where was the product distributed?

FDA's distribution pattern field reads: "US Nationwide."

Is the recall still ongoing?

FDA lists the status as Ongoing. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.

Where does this data come from?

openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.

Provenance

Source: openFDA drug enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.